Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Epilepsy Behav. 2010 Mar;17(3):336-43. doi: 10.1016/j.yebeh.2010.01.001. Epub 2010 Feb 13.
Docosahexaenoic acid (DHA), an omega-3 fatty acid, has been reported to raise seizure thresholds. The purpose of the present study was to test the acute anticonvulsant effects of unesterified DHA in rats, using the maximal pentylenetetrazol (PTZ) seizure model, and also to examine DHA incorporation and distribution into blood serum total lipids and brain phospholipids and unesterified fatty acids. Sedation was measured to monitor for the potential toxicity of DHA.
Male Wistar rats received subcutaneous injections of saline, oleic acid (OA), or DHA. An initial pilot study (Experiment 1) established 400mg/kg as an effective dose of DHA in the maximal PTZ seizure test. A subsequent time-response study, using 400mg/kg (Experiment 2), established 1 hour as an effective postinjection interval for administering DHA subcutaneously. A final study (Experiment 3) comprised two different groups. The first group ("seizure-tested rats") received saline, OA, or DHA (400mg/kg) subcutaneously, and were seizure tested in the maximal PTZ test 1 hour later to confirm the seizure latency measurements at that time. The second group ("assay rats") received identical subcutaneous injections of saline, OA, or DHA (400mg/kg). One hour postinjection, however, they were sacrificed for assay rather than being seizure tested. Assays involved the analysis of serum and brain DHA. Sedation was measured in both Experiment 3 groups during the 1-hour period prior to seizure testing or sacrifice.
As noted above, 400mg/kg proved to be an effective subcutaneous dose of DHA (Experiment 1), and 1 hour proved to be the most effective injection-test interval (Experiment 2). In Experiment 3, in the seizure-tested animals, subcutaneous administration of 400mg/kg of DHA significantly increased latency to PTZ seizure onset 1 hour postinjection relative to the saline- and OA-injected controls, which did not differ significantly from each other (P>0.05). In the assay animals, no significant effects of treatment on blood serum total lipids or on brain phospholipid or unesterified fatty acid profiles (P>0.05) were observed. There were also no differences in sedation among the three groups (P>0.05).
DHA increases resistance to PTZ-induced seizures without altering measures of sedation and, apparently, without changing DHA concentrations in serum or brain.
二十二碳六烯酸(DHA)是一种ω-3 脂肪酸,已被报道能提高癫痫发作阈值。本研究的目的是测试未酯化 DHA 在大鼠中的急性抗惊厥作用,使用最大戊四氮(PTZ)惊厥模型,并检查 DHA 掺入和分布到血清总脂质和脑磷脂和未酯化脂肪酸中。镇静作用的测量用于监测 DHA 的潜在毒性。
雄性 Wistar 大鼠接受生理盐水、油酸(OA)或 DHA 的皮下注射。一项初步的初步研究(实验 1)确定 400mg/kg 是 PTZ 最大惊厥试验中 DHA 的有效剂量。随后的时间反应研究(实验 2)使用 400mg/kg 确定 1 小时是皮下给予 DHA 的有效注射后间隔时间。最后一项研究(实验 3)包括两个不同的组。第一组(“惊厥测试大鼠”)接受生理盐水、OA 或 DHA(400mg/kg)皮下注射,1 小时后在最大 PTZ 试验中进行惊厥测试,以确认当时的惊厥潜伏期测量值。第二组(“测定大鼠”)接受生理盐水、OA 或 DHA(400mg/kg)的相同皮下注射。然而,在注射后 1 小时,它们被处死进行测定,而不是进行惊厥测试。测定包括血清和脑 DHA 的分析。在惊厥测试或处死前的 1 小时期间,在实验 3 组中测量镇静作用。
如前所述,400mg/kg 被证明是一种有效的 DHA 皮下剂量(实验 1),1 小时被证明是最有效的注射-测试间隔(实验 2)。在实验 3 中,在惊厥测试动物中,与生理盐水和 OA 注射对照组相比,400mg/kg 的 DHA 皮下给药在注射后 1 小时显著增加了 PTZ 惊厥发作的潜伏期,对照组之间无显著差异(P>0.05)。在测定动物中,治疗对血清总脂质或脑磷脂或未酯化脂肪酸谱(P>0.05)没有显著影响。三组之间的镇静作用也没有差异(P>0.05)。
DHA 增加了对 PTZ 诱导的惊厥的抵抗力,而不会改变镇静措施,并且显然不会改变血清或大脑中的 DHA 浓度。